Bright Minds Biosciences Inc. — FY2022 Form 20-F
Reporting period: Fiscal year ended September 30, 2022. This is an annual report, not a standalone Q4 report; financial statements are prepared under IFRS and presented in Canadian dollars (C$), unless otherwise noted.
Business context
Bright Minds is a pre-revenue biotechnology company developing selective serotonergic drug candidates for central nervous system disorders, including epilepsy and depression. Its lead 5-HT2C candidate, BMB-101, entered a Phase 1 trial in August 2022. The company relies substantially on consultants and outside research organizations.
Key financial metrics
| Metric (C$ unless stated) | FY2022 / Sep. 30, 2022 | FY2021 / Sep. 30, 2021 |
|---|---|---|
| Revenue | Nil | Nil |
| Net loss | 14,964,941 | 8,650,763 |
| Basic and diluted loss per share | C$(1.21) | C$(0.96) |
| Research and development expense | 12,180,938 | 6,313,988 |
| Cash and cash equivalents | 11,627,913 | 19,760,015 |
| Current assets | 11,948,121 | 20,038,368 |
| Total assets | 12,086,984 | 20,040,368 |
| Current liabilities | 1,472,489 | 638,573 |
| Total liabilities | 1,544,472 | 638,573 |
| Working capital surplus | 10,475,632 | 19,399,795 |
| Net cash used in operating activities | 13,587,116 | 7,319,301 |
No gross profit or operating margin is reported because the company had no revenue. The filing reports no long-term debt; lease liabilities totaled C$139,911 at year-end, including C$67,928 current and C$71,983 non-current.
Changes versus prior year
- Net loss increased approximately 73%, as operating activity expanded. R&D expense rose approximately 93%, driven by continued development across the drug pipeline.
- Year-end cash fell C$8.1 million and working capital fell C$8.9 million. Operating cash use increased, while financing cash inflows were C$5.2 million, compared with C$26.1 million in FY2021.
- FY2022 financing included a C$4.0 million unit offering and proceeds from warrant exercises. The company also recorded C$875,056 in share-based compensation and a C$2,000 impairment of intangible assets.
Outlook, risks and other matters
- Management expects continued losses and negative operating cash flow, and says further equity financing may be needed. The filing discusses a possible need for additional capital after existing funds support operations, but gives no firm cash-runway estimate or financial guidance.
- Going-concern continuity depends on future financing and eventual profitable operations; the company states that financing access is uncertain. Failure to raise capital could force reduced or discontinued operations.
- Key risks include early-stage clinical development, trial delays or adverse safety findings, regulatory approval uncertainty, dependence on third parties, intellectual-property protection, dilution, foreign-exchange movements and share-price volatility.
- Preclinical studies reported activity in animal models, but these results do not establish human safety or efficacy. The Phase 1 trial’s stated objectives include safety, tolerability, pharmacokinetics/pharmacodynamics and exploratory markers.
- After year-end, the company closed a C$2.05 million private placement on December 2, 2022. It also disclosed new CMO compensation and equity awards, including 300,000 options and 1.1 million RSUs granted after year-end.
- The auditor issued an unqualified opinion on the IFRS financial statements and reported no critical audit matters. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not provide an internal-controls attestation.
Important facts for investors to verify
- Net loss discrepancy: The selected financial data table states FY2022 net loss of C$14,962,941, while the audited statements and other sections report C$14,964,941. Confirm the correct figure; the audited statement reports C$14,964,941.
- Cash runway and financing: Verify current cash, subsequent cash burn and financing needs against the C$11.6 million year-end cash balance and C$13.6 million FY2022 operating cash use.
- Share count and dilution: Reconcile the 17,592,359 shares outstanding at September 30, 2022 with the 18,710,359 reported at December 28, 2022, and review outstanding options, warrants and subsequent grants.
- Clinical progress: Check the status, enrollment, safety disclosures and results of the BMB-101 Phase 1 trial; the filing provides no clinical efficacy results.
- License economics: Review the University of Illinois license’s royalties, milestone payments, annual minimums and termination provisions.